Biofrontera (BFRI) Q4 2025 Earnings Transcript

Core Insights - Biofrontera Inc. achieved record annual revenues of $41.7 million in fiscal year 2025, marking a 12% increase from the previous year, with Q4 revenues reaching $17.1 million, a 36% year-over-year growth, indicating strong commercial execution and adoption of Ameluz PDT in dermatology [1][5][21] Financial Performance - The adjusted EBITDA for Q4 2025 was $4.9 million, with a net income of $5.6 million, a significant improvement from a net loss of $1.4 million in Q4 2024 [5][20] - For the full year 2025, total GAAP net revenues were $41.7 million, up from $37.3 million in 2024, driven by organic growth in Ameluz sales [21][22] - The cost of goods sold decreased by 43% to $10.1 million, leading to a gross profit margin improvement from 50% to 74% for the year [22][23] Strategic Developments - Biofrontera completed a significant asset purchase agreement with its former parent company, Biofrontera AG, gaining full U.S. rights and regulatory control over Ameluz and RhodoLED, which is expected to enhance financial performance [5][6][34] - The new royalty structure is set at 12% for annual U.S. Ameluz net sales up to $65 million and 15% for sales exceeding that threshold, replacing a previous model that ranged from 25% to 35% [6][7] Clinical Advancements - The company submitted a supplemental New Drug Application for superficial basal cell carcinoma (sBCC) based on positive Phase III data, with a PDUFA target action date of September 28, 2026 [9][10] - Positive Phase III results were announced for actinic keratosis (AK) on extremities, and Phase II results for moderate to severe acne vulgaris showed a 58% reduction in inflammatory lesions [11][12] Commercial Strategy - Biofrontera's commercial strategy has been refined, leading to a 10% increase in Ameluz unit volumes, with approximately 121,000 tubes sold in 2025 [13][14] - The company placed approximately 85 RhodoLED lamps in dermatology practices, increasing its installed base to about 745 lamps [14][15] Future Outlook - The company anticipates that the full benefits of the new cost structure will be realized in 2026, with expected gross profit margins ranging between 80% and 85% [30][34] - Biofrontera is positioned for continued growth with multiple clinical studies planned and a strengthened patent portfolio extending protection through 2043 [34][35]